Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
S2Medical AB (publ) (S2M.ST)
Linköping, SE
S2Medical AB (publ) focuses on the development, production, and commercialization of advanced wound care solutions, specifically targeting burns and chronic wounds. Their product range features INSTAQRETT, a sterile, disposable tool for mechanical debridement; EPIPROTECT SafeStop, designed to control bleeding; and Instagraft, a single-use medical device for treating complex and prolonged wounds. The company also supplies EPIPROTECT tissue replacement products and INSTABIND-branded bandages, which are known for being washable, waterproof, and self-adhesive. Furthermore, S2Medical distributes Silverlon dressings, which facilitate the delivery of silver ions to the wound. In addition to its product offerings, the company operates specialized wound healing centers known as S2Clinic. Founded in 2013, S2Medical is headquartered in Linköping, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +6.25% | +0.00% | -30.61% | -33.33% | -32.00% | -66.67% | -97.17% | -99.87% | -99.95% | -99.95% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Instruments & Supplies: +7.9%-3.7% Q2'25: +135.2% (vs Q2'24)
-
EPS growth Medical - Instruments & Supplies: +16.3%-214.6% Q2'25: -99.5% (vs Q2'24)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+0.2% Q2'25: +4.1% (vs Q2'24)
-
EBIT margin Medical - Instruments & Supplies: +13.5%-18.7% Q2'25: -7.9% (vs Q2'24)
-
ROIC Medical - Instruments & Supplies: +6.0%-29.9% Q2'25: -7.4% (vs Q2'24)
-
Share dilution Medical - Instruments & Supplies: +0.1%+53.0% Q2'25: +130.8% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.00× Q2'25: 0.00× (vs Q2'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. |
|---|---|---|---|---|---|---|
| Revenue |
7.70M
est: 9.22M (-16.5%)
|
4.67M
est: 13.48M (-65.3%)
|
6.97M
est: 10.82M (-35.5%)
|
14.91M
est: 20.00M (-25.5%)
|
14.36M
est: 40.00M (-64.1%)
|
60.00M
60.00M – 60.00M
+50.0% YoY
|
| EBITDA |
-18.73M
est: -5.71M (-228.1%)
|
-26.37M
est: -8.34M (-216.2%)
|
-13.53M
est: -6.69M (-102.2%)
|
6.82M
est: -10.56M (+164.6%)
|
-1.41M
est: -21.12M (+93.3%)
|
-31.68M
-31.68M – -31.68M
-50.0% YoY
|
| EBIT |
-19.84M
est: -5.90M (-236.1%)
|
-27.69M
est: -8.62M (-221.1%)
|
-15.26M
est: -6.92M (-120.6%)
|
5.79M
est: -11.19M (+151.7%)
|
-2.68M
est: -22.39M (+88.0%)
|
-33.58M
-33.58M – -33.58M
-50.0% YoY
|
| Net Income |
-20.08M
est: -169.67M (+88.2%)
|
-29.46M
est: -130.97M (+77.5%)
|
-22.71M
est: -25.88M (+12.3%)
|
5.77M
est: -33.01M (+117.5%)
|
-10.09M
|
—
— – —
|
| SGA |
12.21M
est: 16.18M (-24.6%)
|
31.54M
est: 23.65M (+33.4%)
|
—
est: 18.98M (-100.0%)
|
—
est: 33.36M (-100.0%)
|
—
est: 66.72M (-100.0%)
|
100.07M
100.07M – 100.07M
+50.0% YoY
|
| EPS |
-0.35
est: -0.30 (-15.5%)
|
-0.45
est: -0.23 (-92.4%)
|
-0.14
est: -0.05 (-202.8%)
|
0.01
est: -0.04 (+126.7%)
|
-0.01
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Marten Skog | Co-Founder, Chief Operating Officer & Director | — | male |
| Petter Sivler | Co-Founder & Chief Executive Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for S2M.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
